Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL681512 | 1.00 | CYP2C19 (0.52) | CYP2C19SMN1; SMN2CYP2D6SRCRIPK1 | |
| SCHEMBL681077 | 1.00 | CYP2C19 (0.52) | CYP2C19SMN1; SMN2CYP2D6SRCRIPK1 | |
| SCHEMBL679846 | 0.86 | RIPK1 (0.45) | CYP2C19CYP2D6SRCRIPK1LMNA | |
| SCHEMBL28477577 | 0.86 | CYP2C19 (0.55) | CYP2C19SMN1; SMN2CYP2D6SRCRIPK1 | |
| SCHEMBL28347593 | 0.86 | CYP2C19 (0.50) | CYP2C19SMN1; SMN2CYP2D6SRCRIPK1 | |
| SCHEMBL681511 | 0.86 | RIPK1 (0.45) | CYP2C19CYP2D6SRCRIPK1LMNA | |
| SCHEMBL679850 | 0.86 | RIPK1 (0.45) | CYP2C19CYP2D6SRCRIPK1LMNA | |
| SCHEMBL27886529 | 0.85 | ESR1 (0.47) | CYP2C19CYP2D6SRCPOLBLMNA | |
| SCHEMBL28437022 | 0.83 | CYP2C19 (0.47) | CYP2C19SMN1; SMN2CYP2D6SRCRIPK1 | |
| SCHEMBL29113951 | 0.83 | CYP2C19 (0.47) | CYP2C19SMN1; SMN2CYP2D6SRCRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063050-B2 | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | CYP2C19 1175/4885SMN1; SMN2 3564/4885CYP2D6 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.